These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32546414)

  • 1. Adverse events following immunization with the live-attenuated recombinant Japanese encephalitis vaccine (IMOJEV®) in Taiwan, 2017-18.
    Ma HY; Lai CC; Chiu NC; Lee PI
    Vaccine; 2020 Jul; 38(33):5219-5222. PubMed ID: 32546414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand.
    Chotpitayasunondh T; Pruekprasert P; Puthanakit T; Pancharoen C; Tangsathapornpong A; Oberdorfer P; Kosalaraksa P; Prommalikit O; Tangkittithaworn S; Kerdpanich P; Techasaensiri C; Korejwo J; Chuenkitmongkol S; Houillon G
    Vaccine; 2017 Jan; 35(2):299-304. PubMed ID: 27903416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.
    Rabe IB; Miller ER; Fischer M; Hills SL
    Vaccine; 2015 Jan; 33(5):708-12. PubMed ID: 25498208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.
    Chotpitayasunondh T; Suntarattiwong P; Yoksan S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2407663. PubMed ID: 39353860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a single fractional intradermal dose of Japanese encephalitis live attenuated chimeric vaccine.
    Furuya-Kanamori L; Gyawali N; Mills DJ; Mills C; Hugo LE; Devine GJ; Lau CL
    J Travel Med; 2023 Apr; 30(2):. PubMed ID: 36308439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016.
    Walker WL; Hills SL; Miller ER; Fischer M; Rabe IB
    Vaccine; 2018 Jul; 36(29):4369-4374. PubMed ID: 29891351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.
    Nasveld PE; Ebringer A; Elmes N; Bennett S; Yoksan S; Aaskov J; McCarthy K; Kanesa-thasan N; Meric C; Reid M
    Hum Vaccin; 2010 Dec; 6(12):1038-46. PubMed ID: 21150279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
    Appaiahgari MB; Vrati S
    Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.
    Ginsburg AS; Meghani A; Halstead SB; Yaich M
    Hum Vaccin Immunother; 2017 Oct; 13(10):2222-2231. PubMed ID: 28841362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of IMOJEV ®--a recombinant Japanese encephalitis chimeric vaccine (JE-CV).
    Appaiahgari MB; Vrati S
    Expert Opin Biol Ther; 2012 Sep; 12(9):1251-63. PubMed ID: 22775524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
    Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
    Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
    Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.